Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373903 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly
A Phase 2 study of Respiratory Tract Infections, sponsored by Restorbio.
- Active
- Registry status
- Phase 2
- Development phase
- 652
- Enrollment target
- 1
- Study location
NCT03373903: Active Phase 2 study of Respiratory Tract Infections, sponsored by Restorbio.
NCT03373903 is a Phase 2 study of Respiratory Tract Infections that is active but no longer recruiting, run by Restorbio. The registered enrollment target is 652 participants, below the 2,731-participant average among 15 other Respiratory Tract Infections trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03373903, a Phase 2 study of Respiratory Tract Infections, is active but no longer recruiting, sponsored by Restorbio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 652 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BEZ235
- DRUG BEZ235 plus everolimus (RAD001)
Study Locations (1)
Kansas
- Heartland Research Associates - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 652 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2018-07 |
| Phase | Phase 2 |
What the registry record for NCT03373903 still lists
NCT03373903 is an interventional study that assigns participants to a tested intervention. The registered 652 participants enrollment target is mid-sized for trials with a published cap, below the 2,731-participant average among 15 other Respiratory Tract Infections trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Respiratory Tract Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03373903 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03373903 about?
NCT03373903 is a clinical study titled "Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly". The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
What is the current status of trial NCT03373903?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 652 participants. The study started on 2017-11-15. Estimated completion is 2018-07.
What conditions does trial NCT03373903 study?
This clinical trial studies the following conditions: Respiratory Tract Infections.
What interventions are being tested in trial NCT03373903?
The interventions under investigation include: Placebo (OTHER), BEZ235 (DRUG), BEZ235 plus everolimus (RAD001) (DRUG).
Who is sponsoring clinical trial NCT03373903?
This trial is sponsored by Restorbio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03373903 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03373903's enrollment target sits among peer trials
652 6th of 15 higher than 10 of 15 other Respiratory Tract Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Tract Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Beetroot Juice NO Cold Study
RECRUITING · Phase 2
-
Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses
RECRUITING · NA
-
How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.
RECRUITING · NA
-
An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.
RECRUITING · NA
-
A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age
COMPLETED · Phase 1
-
Rapid Detection of Airway Pathogens for Lung Transplantation
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06287346 · 652 participants
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI